Emily Chan

Company: Amgen Inc.

Job title: Medical Director, Clinical Research

Seminars:

The Story of Sotorasib: The First Clinical Journey of the First Approved RAS-Targeted Drug 8:30 am

Sotorasib: From first in human to first accelerated approval in under 3 years – A case-study for drug approval A look back: Lessons learned from the journey of Sotorasib into the clinic and beyond A look forward: Latest clinical development updatesRead more

day: Conference Day Two

Make it a Combo Meal: Exploring Combination Therapies that Assist RAS-Targeted Drugs in Ensuring Cancer Free Survival 3:01 pm

Given the RAS pathway’s importance to normal cell homeostasis, it has evolved to be a naturally robust pathway that is difficult to disrupt. For a few years now, it has become clear that RAStargeted drugs work more effectively when combined with other therapies, such as inhibitors up/ downstream of RAS, immune checkpoint inhibitors and various…Read more

day: Workshop C